Lilly deploys obesity cash into $3.8B vaccine buying spree

Eli Lilly (NYSE:LLY) announced an aggressive expansion into the infectious disease prevention sector, entering into definitive agreements to acquire three distinct vaccine developers for a combined potential value of up to $3.83 billion in cash.

The Indianapolis-based pharmaceutical giant is leveraging cash generated from its blockbuster diabetes and obesity franchises to establish an immediate, multi-phase vaccine pipeline.

The three transactions—individually spanning late-stage, early-stage, and preclinical assets—signal Lilly’s intention to compete directly in a preventive health market historically dominated by industry incumbents.

The acquisition structures consist of upfront cash considerations supplemented by tiered development and commercial milestone bonuses.

Under the terms of the individual agreements, Curevo shareholders could receive up to $1.5 billion in total cash.

The acquisition centers on Curevo's lead candidate, amezosvatein, an adjuvanted subunit vaccine for shingles prevention in adults.

In Phase 2 clinical trials, the asset matched the immune response of the current standard of care while reducing common, activity-limiting side effects—including severe fatigue, chills, and site pain—by more than half.

Lilly will acquire Switzerland-based LimmaTech Biologics AG for up to $780 million in cash.

LimmaTech develops vaccines against complex bacterial pathogens, including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis.

Its lead program, LTB-SA7, is currently undergoing Phase 1 evaluation.

The final component is an agreement to acquire Vaccine Company for up to $1.55 billion in cash.

Vaccine Company utilizes proprietary In Vivo Nanoparticle (IVN) technologies for viral pathogen platforms.

Its lead asset is a five-antigen, Phase 1-ready candidate targeting the highly prevalent Epstein-Barr Virus (EBV), which has been increasingly linked to long-term neurological and oncological complications, including multiple sclerosis and several cancers.

The strategic pivot comes as Lilly seeks to diversify its long-term pipeline.

Decades of clinical evidence have increasingly linked common acute primary infections to long-term chronic diseases emerging years later, while escalating antimicrobial resistance continues to erode the efficacy of traditional treatments for bacterial infections.

All three transactions are expected to navigate standard regulatory reviews during the first half of fiscal year 2026.